This article was originally published in The Gray Sheet
Submits premarket approval application for Telio-Derm wound healing agent for the treatment of chronic dermal ulcers associated with diabetes. A study supporting the PMA filing showed a "fourfold increase in the number of ulcers completely healed in the Telio-Derm group compared to the control group," according to the company. Telios also plans to apply its technology to the treatment of ophthalmic and other types of severe and chronic dermal wounds.
You may also be interested in...
Officials from the US Food and Drug Administration cited their reasons for refusing to review new applications for companies with unresolved data integrity failures.
However, Vaccinex sees possible efficacy for SEMA4D inhibition in later-stage Huntington’s as well as Alzheimer’s disease. Pepinemab is also being studied with Keytruda in head-and-neck cancer.
In last year’s acquisition, Bristol Myers Squibb agreed to pay Celgene investors another $9 per share based on three approvals, including idecabtagene vicleucel (bb2121) by 30 March 2021.